基本信息
views: 121
Career Trajectory
Bio
MD in Clinical Medicine; MS in Clinical Oncology; PhD in Oncology; Attending Physician – Oncology. My research interests are Cancer Immunotherapy, Nanomedicine and Cancer Stem Cell.
1. Delivery of anti-cancer drugs (e.g., paclitaxel, p53 protein, etc.) and tumor antigenic peptides with Nanotechnology since 2002 and 2005, respectively.
2. Identification of 2 novel HLA-A2 restricted CTL epitopes with stronger immunogenicity than natural Survivin (SV95-104) peptide, and obtainment of higher Survivin-specific CTL clones in 2007.
3. Discovery of cancer stem cell (CSC) markers in T-cell acute lymphoblastic leukemia (T-ALL) and treatment of cancer types driven by Notch1 oncogene (WO2013044164 international Invention patent).
20 years of animal model experience
Hands on surgical skills demonstrated with surgery of sewing bioprinted tissues onto mouse liver worked with Organovo Inc. (San Diego, CA). Establishment of humanized mouse models (e.g., leukemia, brain tumor, breast cancer, prostate cancer, and normal stem cells, etc.) via transplantation routes of intrahepatic, intravenous, and intracerebral ventricular injections, etc.
5 years General Surgical Resident
3 years Surgical Oncologist Fellow specializing in thyroid and breast cancers.
2 years Attending Medical Oncologist
5 years Postdoc Researcher: 2 years at UNMC focused on cancer treatment with Nanomedicine, 1 year at UW-Madison studied on Molecular Immunology specialized in activated immune cells, and 2 years at UC San Diego dedicated to Cancer Immunotherapy and clinical trials with tumor antigen-specific cytotoxic T lymphocytes.
6 years Asst. Project Scientist at UC San Diego (2007-2013)
6 years Assoc. Project Scientist at UC San Diego (2013-2020)
2 years Project Scientist at UC San Diego (2020-Current)
1 year Dean and Distinguished Professor at Huzhou University School of Medicine (2013-2014)
1 year Senior Scientist at Cynvenio Biosystems Inc. (CTC and NGS, 2014-2015)
16 years Peer reviewers for 42 journals (e.g., Cancer Immunology Research, Frontiers in Immunology, Int Journal of Cancer, Cancers, Molecular Oncology, Oncotarget, Nanomedicine, etc.) and 6 editorial board members since 2006. Awarded "Outstanding Reviewer" from the journal of《Cellular Immunology》. Guest Editor of《Cancers》(Jan. 2022 - Current).
38 peer-reviewed papers published with a total impact factor around 309 and citation over 2684.
Current Research Works: Treatment of LSC and solid tumor (TNBC) with small molecule splicing modulator, a new drug candidate.
Memberships: ASCO, ASH, AACR, and ISSCR.
1. Delivery of anti-cancer drugs (e.g., paclitaxel, p53 protein, etc.) and tumor antigenic peptides with Nanotechnology since 2002 and 2005, respectively.
2. Identification of 2 novel HLA-A2 restricted CTL epitopes with stronger immunogenicity than natural Survivin (SV95-104) peptide, and obtainment of higher Survivin-specific CTL clones in 2007.
3. Discovery of cancer stem cell (CSC) markers in T-cell acute lymphoblastic leukemia (T-ALL) and treatment of cancer types driven by Notch1 oncogene (WO2013044164 international Invention patent).
20 years of animal model experience
Hands on surgical skills demonstrated with surgery of sewing bioprinted tissues onto mouse liver worked with Organovo Inc. (San Diego, CA). Establishment of humanized mouse models (e.g., leukemia, brain tumor, breast cancer, prostate cancer, and normal stem cells, etc.) via transplantation routes of intrahepatic, intravenous, and intracerebral ventricular injections, etc.
5 years General Surgical Resident
3 years Surgical Oncologist Fellow specializing in thyroid and breast cancers.
2 years Attending Medical Oncologist
5 years Postdoc Researcher: 2 years at UNMC focused on cancer treatment with Nanomedicine, 1 year at UW-Madison studied on Molecular Immunology specialized in activated immune cells, and 2 years at UC San Diego dedicated to Cancer Immunotherapy and clinical trials with tumor antigen-specific cytotoxic T lymphocytes.
6 years Asst. Project Scientist at UC San Diego (2007-2013)
6 years Assoc. Project Scientist at UC San Diego (2013-2020)
2 years Project Scientist at UC San Diego (2020-Current)
1 year Dean and Distinguished Professor at Huzhou University School of Medicine (2013-2014)
1 year Senior Scientist at Cynvenio Biosystems Inc. (CTC and NGS, 2014-2015)
16 years Peer reviewers for 42 journals (e.g., Cancer Immunology Research, Frontiers in Immunology, Int Journal of Cancer, Cancers, Molecular Oncology, Oncotarget, Nanomedicine, etc.) and 6 editorial board members since 2006. Awarded "Outstanding Reviewer" from the journal of《Cellular Immunology》. Guest Editor of《Cancers》(Jan. 2022 - Current).
38 peer-reviewed papers published with a total impact factor around 309 and citation over 2684.
Current Research Works: Treatment of LSC and solid tumor (TNBC) with small molecule splicing modulator, a new drug candidate.
Memberships: ASCO, ASH, AACR, and ISSCR.
Research Interests
Papers共 117 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
FRONTIERS IN IMMUNOLOGY (2024): 1332057-1332057
Frontiers in immunology (2024): 1376045-1376045
Cancer Letters (2024): 217072-217072
CYTOKINE & GROWTH FACTOR REVIEWS (2024): 12-21
ONCOLOGY RESEARCHno. 1 (2024): 49-60
CANCER SCIENCEno. 4 (2024): 1060-1072
Oncology researchno. 1 (2024): 95-98
Maria Dolores Rivera,Haoran Zhang, Qingchen Zhou,Jessica Pham,Jane Isquith,Roman Sasik,Adam Mark, Sabina Enlund,Frida Holm,Ma Wenxue,Kathleen Fisch, Dennis Kuo,
Cancer Researchno. 6_Supplement (2024): 5448-5448
Inge van der Werf,Larisa Balaian,Jessica Pham,Wenxue Ma, Athena Mohebbi, Emma Klacking, Antonio Ruiz, Karla Mack, John Mascarenhas,Thomas Whisenant,Ludmil Alexandrov,Sheldon Morris,
Cancer Researchno. 6_Supplement (2024): 263-263
crossref(2023)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn